Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Alzheimer’s Research Forges Ahead

October 13, 2010 11:21 am | by Catherine Shaffer, Contributing Writer | Articles | Comments

Alzheimer’s disease (AD) has been one of the most hotly pursued—and most elusive—therapeutic areas in biomedical research. Currently, there are no disease-modifying therapies available.


Stem Cell Screening

October 13, 2010 8:49 am | Product Releases | Comments

Plasticell, the biotechnology company specialising in high throughput screening for stem cell differentiation, has launched its second generation CombiCult 10,000-plex screen capable of rapidly screening up to ten thousand cell culture media combinations.


New Step Towards Cure for CF

October 13, 2010 8:41 am | News | Comments

A University of Missouri researcher believes his latest work moves scientists closer to a cure for cystic fibrosis, one of the world's most common fatal genetic diseases.


Personal Genetic Profiling Services Lack Evidence For Claims

October 13, 2010 8:32 am | News | Comments

Direct-to-consumer personal genetic profiling services that claim to predict people's health risks by analysing their DNA are often inconclusive and companies that sell them should provide better information about the evidence on which the results are based.


Covance Collaborating with INphoton

October 13, 2010 8:29 am | News | Comments

Covance and INphoton LLC announced a collaborative relationship which will grant Covance exclusive global access to INphoton’s intravital microscopy imaging technology and expertise.


Expression Analysis Expands Services

October 13, 2010 8:26 am | News | Comments

Expression Analysis, a leading provider of genomic services for clinical trials and research, announced that it has expanded its sequencing services to include single-lane sequencing with guaranteed turn-around-times and, firm fixed pricing.


Merck Presents Positive Erbitux Data

October 13, 2010 8:20 am | News | Comments

Merck KGaA announced data presented that showed that patients with KRAS wild-type metastatic colorectal cancer who experienced early tumor shrinkage during first-line Erbitux-based treatment lived a median of 28.3 months.


Prosensa Gets Milestone Payment from GSK

October 13, 2010 8:09 am | News | Comments

Prosensa received a £7.5m milestone payment from GlaxoSmithKline as a result of achieving a data milestone in its Phase 2a open label extension trial of GSK2402968 (PRO051), being developed to treat Duchenne Muscular Dystrophy.


FDA Approves Vivitrol for Drug Addiction

October 13, 2010 8:06 am | News | Comments

Drugmaker Alkermes Inc. said it has received U.S. approval to market its addiction medication for use in patients addicted to narcotics like heroin and morphine.


HIV Patients To Be Screened for TB

October 13, 2010 8:04 am | by Jenny Gross | News | Comments

Health officials in South Africa said they recommend screening all HIV patients for tuberculosis and want automatic TB tests for HIV patients to become normal procedure within five years.


Treating Relapsing-Remitting Multiple Sclerosis

October 13, 2010 7:43 am | by Kate Dawson, MD, Senior Director, Medical Research, Biogen Idec, Cambridge, Mass. | Articles | Comments

Biogen Idec’s BG-12 is an oral formulation of dimethyl fumarate. This is the first compound in clinical trials to activate the Nrf2 transcriptional pathway, a central mechanism of cellular defense against oxidative and metabolic stress.


Therapeutic Promise of Human Neural Stem Cells

October 13, 2010 7:39 am | by Stephen Huhn, MD, FACS, FAAP, Vice President, Head of the CNS Program, StemCells, Inc., Palo Alto, Calif. | Articles | Comments

Stem cells have the potential to treat a broad range of human disorders. While approaches based on embryonic stem cells and induced pluripotent stem cells have attracted the most media attention, they are complicated by specific challenges.


Unlocking the Therapeutic Potential of the NMDA Receptor

October 13, 2010 7:36 am | by Joseph R. Moskal, PhD, President and CSO; J. David Leander, PhD, Chief Scientific Advisor; and Ronald M. Burch, MD, PhD, CMO, Naurex, Inc., Evanston, Ill. | Articles | Comments

The glutamate receptor subtype known as N-methyl-D-aspartic acid (NMDA) plays a central role in modulating aspects of brain activity. Naurex is developing a pipeline that modulates the NMDA receptor (NMDAR) at the glycine site.


Glutamate Modulation as Parkinson’s Therapy

October 13, 2010 7:28 am | by Chris Maggos, Investor Relations & Communication, Addex Pharmaceuticals, Geneva, Switzerland | Articles | Comments

Glutamate is a critical neurotransmitter that is involved in a multitude of biological functions and disease processes. Despite its rich therapeutic potential, the glutamatergic system has historically been a challenge for drug discoverers.


HuCAL Antibody Combats Alzheimer’s Disease

October 13, 2010 7:22 am | by Marlies Sproll, PhD, CSO MorphoSys AG Planegg, Germany | Articles | Comments

A major challenge for Alzheimer’s disease drug candidates, particularly for therapeutic antibodies, is the blood-brain barrier. Once considered impermeable for large molecules, recent evidence has shown that they are in fact able to pass through.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.